Notal Vision

Notal Vision has developed a cloud-based platform designed to effectively and efficiently address large unmet diagnostic, economic, and social needs in the area of ophthalmology. The company's integrated platform uses AI algorithms to detect and provide diagnostic decision support, driving at-home testing and patient-activated treatment. Using a monthly recurring subscription service model, the platform provides the basis for cost-effective solutions that can enhance both compliance and outcomes. Notal's ForeseeHome is an FDA-approved home monitoring test that supports earlier detection of wet age-related macular degeneration (AMD) in people with intermediate dry AMD. It is available only by physician order and covered by US Medicare. Notal also develops a home optical coherence tomography (OCT) solutions, noninvasive imaging technology for viewing retinal anatomy and assessing the need for treatment of age-related eye diseases that lead to blindness. In December 2018, Notal's Home OCT was granted Breakthrough status by the FDA and selected to participate in the FDA's OCT Innovation Pilot program. Notal's OCT Analyzer is a computational image analysis algorithm designed to provide automated detection of fluid in exudative retinal diseases.

Notal Vision has raised $94.05M in total funding across 6 rounds. The company is currently at the D stage. Key investors include Elron Ventures, Evergreen Venture Partners, Soleus Capital .

Notal Vision operates in Health Tech & Life Sciences, Digital Healthcare, Digital Medical Diagnostics, with core technologies in Data Storage, Cloud, Artificial Intelligence, Simulation & Imaging. Target customers: Consumers, Demographics & Family, Seniors, Healthcare & Life Sciences, Healthcare, Providers.

Notal Vision is based in Druyanov Street 5, Tel Aviv-Yafo, Israel, Center District. The company also has offices abroad.